RE:Weak resultsThey were transitioning to the new facility and thus this may not be a clean quarter. With the transition now complete the results going forward may be more indicative. Q1 results are due shortly. Sales quarter-to-quarter can also be lumpy given when client orders are placed and on an annual basis revenues were up 36%. With the lower Canadian dollar in 2015 the company is set to benefit. The company does say it is more confident than ever in what is ahead:
"We are more confident than ever that Ceapro has the key to new successes by offering: a de-risked business model with a base business in the cosmetic sector, which provides a revenue stream; well advanced near-term catalysts with dry beta glucan as a potential functional food/nutraceutical; and long-term catalysts with dry formulations of avenanthramides for the nutraceutical and/or pharmaceutical markets. Also, we view the development of our proprietary PGX platform technology for which we have recently obtained the worldwide rights for all industrial applications as a game changer for Ceapro."
Read more at https://www.stockhouse.com/news/press-releases/2015/04/22/ceapro-reports-record-full-year-2014-financial-results#biZPvZpzXxMbOaus.99